Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Overexpression of CSF-1 and/or FMS has been implicated in a number of disease states such as the growth of metastasis of certain types of cancer, in promoting osteoclast proliferation in bone osteolysis, and many inflammatory disorders.
|
22434539 |
2013 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
This work expands what is known on the non-macrophage functions of CSF-1R and its role in solid tumors, and suggests that CSF-1R signaling may have a critical pathogenic role in a prototypical, inflammation-related cancer such as MPM and therefore may represent a promising target for therapeutic intervention.
|
24722292 |
2014 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Tyrosine kinases including LCK and FMS are involved in inflammatory disorders as well as many types of cancer.
|
29107425 |
2017 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Nearly all tested combinations involving a BCL2 inhibitor showed additional benefit in patients with myeloid malignancies, whereas select combinations involving PI3K, CSF1R, or bromodomain inhibitors showed preferential benefit in lymphoid malignancies.
|
28784769 |
2017 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Therapeutic antibodies targeting colony stimulating factor 1 receptor (CSF-1R) to block colony stimulating factor-1/colony stimulating factor 1 receptor (CSF-1/CSF-R) signaling axis have exhibit remarkable efficacy in the treatment of malignant tumor.
|
29218239 |
2017 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis revealed an intense CSF‑1/CSF‑1R expression in the cytoplasm of cancer cells in primary GC tissues.
|
29767252 |
2018 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
|
28716061 |
2017 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Analysis of RNA-seq data of 1006 cell lines from the Cancer Cell Line Encyclopedia (CCLE) revealed that more than 12% of carcinoma cell lines expressed markedly elevated mRNA levels of colony-stimulating factor (CSF)-1 receptor (CSF-1R).
|
30075184 |
2018 |
Malignant Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Cases in point are the detection of RAS and FMS mutations in healthy individuals who had been treated in the past with cytotoxic therapy for lymphoma, the frequent observation of clonal remission in AML patients, or the identification of oncogene mutations in healthy individuals without even a history of malignancy or chemotherapy.
|
1613006 |
1992 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
One of the most potent inhibitor 10d, 1-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-2,3-dihydro-1H-thieno [3,4-b][1,4]diazepin-4-yl)phenyl)urea was found to be very potent inhibitor of multi-protein kinases including FMS kinase (IC<sub>50</sub> = 3.73 nM) and is a promising candidate for further development in therapeutics for cancer.
|
29459144 |
2018 |
Malignant Neoplasms
|
0.600 |
CausalMutation
|
group |
CGI |
|
|
|
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
|
31438996 |
2019 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
|
18694641 |
2008 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Here, we show that human osteosarcomas contain CSF-1R-expressing cancer subpopulations, and demonstrate that osteosarcoma cell-intrinsic CSF-1R promotes growth in vitro and in vivo.
|
28469954 |
2017 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
c-fms is present in primary tumours as well as in their metastases in bone marrow.
|
1390197 |
1992 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
More importantly, the dual FMS and KIT inhibition profile has translated into a combination of benefits in preclinical disease models of inflammation and cancer.
|
23493555 |
2013 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Because of the role of this signaling pathway in the tumor microenvironment, several small molecule CSF1R kinase inhibitors are undergoing clinical evaluation for cancer therapy, either as a single agent or in combination with other cancer therapies, including immune checkpoint inhibitors.
|
28377059 |
2017 |
Malignant Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
This CSF-1R/c-FMS is over expressed in many cancers and on tumour associated macrophages, consequently, have been exploited as a drug target for promising treatment for cancer and inflammatory diseases.
|
29679908 |
2018 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We show here that functional CSF-1Rs are present at the nuclear envelope of various cell types, including primary macrophages, human cancer cell lines, and primary human carcinomas.
|
22084313 |
2012 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> Targeting tumor-associated macrophages with colony-stimulating factor 1 receptor (CSF-1R) inhibition reveals a strategy for cancer therapy.
|
28724665 |
2017 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
However, the correlation between CSF1R/DAPK1 signalling pathways and cancer progression provides motives to reprofile them against cancer therapy.
|
31809612 |
2020 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Combination therapy using tyrosine kinase inhibitors (FGFR or CSF1R inhibitors) and immune checkpoint blockers (anti-PD-1 or anti-CTLA-4 monoclonal antibodies) may be a promising choice for cancer patients.
|
27245147 |
2016 |
Malignant Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
CSF1R also provides critical autocrine signals that promote cancer cell survival and proliferation.
|
29323162 |
2018 |
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Loss of methylation and associated overexpression of the CSF 1 receptor (CSF1R) was seen in a majority of tumors and was driven by an alternative, endogenous viral promoter in a subset of samples.
|
30046005 |
2018 |
Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Immunophenotypically, FMS-1 cells showed almost the same characteristics as the primary tumor.
|
19921253 |
2009 |